Access
To read this story in full you will need to login or make a payment (see right).
Business
Nature 447, 131 (10 May 2007) | doi:10.1038/447131a; Published online 9 May 2007
Open Innovation Challenges
-
Direct Molecular Detection of Proteins and Nucleic Acids
This Challenge is looking for novel approaches to protein and nucleic acid detection. This is an Id...
-
Optimizing Sub-cellular Localization Tags
The Seeker is looking for methods to optimize sub-cellular localization tags for protein expression....
- More Challenges
- Powered by:
nature jobs
Assistant or Associate Professor - Cell & Systems Biology
- University of Toronto
- Toronto, ON Canada
Manager for the Recently Established Fly Facility
- Max-Planck-Institute of Immunobiology
- Freiburg Germany
Cheap at any price?
Abstract
As AstraZeneca shells out $15 billion for a mid-sized US biotech firm, Heidi Ledford reports on the startling cost of staying in the drugs business.
When MedImmune, a Maryland biotechnology company, announced on 12 April that it was looking for a buyer, market watchers were unsurprised. Shareholders had long been calling for just such a sale as the best remedy for the company's poor stock performance and sluggish revenue growth — and rumours of an impending deal were already doing the rounds.
To read this story in full you will need to login or make a payment (see right).
